RecruitingNot ApplicableNCT04174755

Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

Sponsor

University College Dublin

Enrollment

80 participants

Start Date

Jun 22, 2022

Study Type

INTERVENTIONAL

Conditions

Obesity HIV-1-infection

Summary

The prevalence of obesity is rising worldwide, both in low- and high-income countries, including people with HIV (PWH). Semaglutide's efficacy in achieving weight loss in obese PWH is still unexplored. The aim of this study is to assess the efficacy and safety of semaglutide in achieving greater weight loss compared to diet and excercise alone in obese PWH and to explore the effect of semaglutide on the immune function, markers of immune activation, viral reservoir, markers of glucose and lipid metabolism and gut microbiome.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether semaglutide — an injectable medication commonly used for type 2 diabetes and obesity — can help people living with HIV lose weight safely and effectively. **You may be eligible if...** - You are 18 or older - You are HIV-positive and have been on stable HIV medication for at least 2 years - Your HIV viral load is undetectable (below 40 copies/mL) - Your CD4 immune cell count is 200 or higher - You have a BMI of 30 or above (obese), or BMI of 27+ with high blood pressure, high cholesterol, or type 2 diabetes **You may NOT be eligible if...** - You have a personal or family history of thyroid cancer or certain other cancers - You have uncontrolled diabetes or a history of severe pancreatitis - You are pregnant or planning to become pregnant - You are already taking semaglutide or similar GLP-1 medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSemaglutide Injectable Product

Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.

BEHAVIORALStandard of care

Diet and exercise advice for 40 weeks